| Dr Jason L Port, MD | |
|
3640 Main St, Suite 101, Springfield, MA 01107-1145 | |
| (413) 781-9000 | |
| (413) 781-7988 |
| Full Name | Dr Jason L Port |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 36 Years |
| Location | 3640 Main St, Springfield, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114033396 | NPI | - | NPPES |
| 3154656 | Medicaid | MA | |
| J16771 | Other | MA | BLUE CROSS BLUE SHIELD OF MASSACHUSETTS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085N0700X | Radiology - Neuroradiology | 151546 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Holyoke Medical Center | Holyoke, MA | Hospital |
| Windham Community Memorial Hospital | Willimantic, CT | Hospital |
| Day Kimball Hospital | Putnam, CT | Hospital |
| Manchester Memorial Hospital | Manchester, CT | Hospital |
| Griffin Hospital | Derby, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Connecticut Imaging Partners Llc | 4183649098 | 83 |
| Farmington Imaging Center Llc | 7719265651 | 55 |
| Connecticut Imaging Partners Llc | 4183649098 | 83 |
| Tic Llc | 4880972819 | 31 |
| Farmington Imaging Center Llc | 7719265651 | 55 |
| Jefferson Radiology Pc | 8729982525 | 89 |
News Archive
Bristol-Myers Squibb Company and Ambrx, Inc. today announced a collaboration under which Bristol-Myers Squibb will receive exclusive worldwide rights to research, develop and commercialize biologics based on Ambrx's research surrounding the Fibroblast Growth Factor 21 protein, for potential use in treating type 2 diabetes, and the Relaxin hormone, for potential use in treating heart failure.
The mitotic spindle, an apparatus that segregates chromosomes during cell division, may be more complex than the standard textbook picture suggests, according to researchers at the Harvard School of Engineering and Applied Sciences.
NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company's third compound to enter the clinic. NOX-H94 is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism.
"The Alzheimer's Association is disappointed to learn of the negative results from the Phase III clinical trial of latrepirdine (Dimebon)," said William Thies, Ph.D., Alzheimer's Association Chief Medical and Scientific Officer. "People with Alzheimer's, their families and caregivers desperately need more and better treatment options for this devastating, fatal brain disease."
› Verified 5 days ago
| Entity Name | Chelmsford Mri Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386662112 PECOS PAC ID: 9537118609 Enrollment ID: O20050114000678 |
News Archive
Bristol-Myers Squibb Company and Ambrx, Inc. today announced a collaboration under which Bristol-Myers Squibb will receive exclusive worldwide rights to research, develop and commercialize biologics based on Ambrx's research surrounding the Fibroblast Growth Factor 21 protein, for potential use in treating type 2 diabetes, and the Relaxin hormone, for potential use in treating heart failure.
The mitotic spindle, an apparatus that segregates chromosomes during cell division, may be more complex than the standard textbook picture suggests, according to researchers at the Harvard School of Engineering and Applied Sciences.
NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company's third compound to enter the clinic. NOX-H94 is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism.
"The Alzheimer's Association is disappointed to learn of the negative results from the Phase III clinical trial of latrepirdine (Dimebon)," said William Thies, Ph.D., Alzheimer's Association Chief Medical and Scientific Officer. "People with Alzheimer's, their families and caregivers desperately need more and better treatment options for this devastating, fatal brain disease."
› Verified 5 days ago
| Entity Name | Chelmsford Mri Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821435553 PECOS PAC ID: 9537118609 Enrollment ID: O20130926000109 |
News Archive
Bristol-Myers Squibb Company and Ambrx, Inc. today announced a collaboration under which Bristol-Myers Squibb will receive exclusive worldwide rights to research, develop and commercialize biologics based on Ambrx's research surrounding the Fibroblast Growth Factor 21 protein, for potential use in treating type 2 diabetes, and the Relaxin hormone, for potential use in treating heart failure.
The mitotic spindle, an apparatus that segregates chromosomes during cell division, may be more complex than the standard textbook picture suggests, according to researchers at the Harvard School of Engineering and Applied Sciences.
NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company's third compound to enter the clinic. NOX-H94 is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism.
"The Alzheimer's Association is disappointed to learn of the negative results from the Phase III clinical trial of latrepirdine (Dimebon)," said William Thies, Ph.D., Alzheimer's Association Chief Medical and Scientific Officer. "People with Alzheimer's, their families and caregivers desperately need more and better treatment options for this devastating, fatal brain disease."
› Verified 5 days ago
| Entity Name | Connecticut Imaging Partners Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740315761 PECOS PAC ID: 4183649098 Enrollment ID: O20141201001337 |
News Archive
Bristol-Myers Squibb Company and Ambrx, Inc. today announced a collaboration under which Bristol-Myers Squibb will receive exclusive worldwide rights to research, develop and commercialize biologics based on Ambrx's research surrounding the Fibroblast Growth Factor 21 protein, for potential use in treating type 2 diabetes, and the Relaxin hormone, for potential use in treating heart failure.
The mitotic spindle, an apparatus that segregates chromosomes during cell division, may be more complex than the standard textbook picture suggests, according to researchers at the Harvard School of Engineering and Applied Sciences.
NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company's third compound to enter the clinic. NOX-H94 is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism.
"The Alzheimer's Association is disappointed to learn of the negative results from the Phase III clinical trial of latrepirdine (Dimebon)," said William Thies, Ph.D., Alzheimer's Association Chief Medical and Scientific Officer. "People with Alzheimer's, their families and caregivers desperately need more and better treatment options for this devastating, fatal brain disease."
› Verified 5 days ago
| Entity Name | Farmington Imaging Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275987802 PECOS PAC ID: 7719265651 Enrollment ID: O20170119002813 |
News Archive
Bristol-Myers Squibb Company and Ambrx, Inc. today announced a collaboration under which Bristol-Myers Squibb will receive exclusive worldwide rights to research, develop and commercialize biologics based on Ambrx's research surrounding the Fibroblast Growth Factor 21 protein, for potential use in treating type 2 diabetes, and the Relaxin hormone, for potential use in treating heart failure.
The mitotic spindle, an apparatus that segregates chromosomes during cell division, may be more complex than the standard textbook picture suggests, according to researchers at the Harvard School of Engineering and Applied Sciences.
NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company's third compound to enter the clinic. NOX-H94 is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism.
"The Alzheimer's Association is disappointed to learn of the negative results from the Phase III clinical trial of latrepirdine (Dimebon)," said William Thies, Ph.D., Alzheimer's Association Chief Medical and Scientific Officer. "People with Alzheimer's, their families and caregivers desperately need more and better treatment options for this devastating, fatal brain disease."
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jason L Port, MD 212 Farmington Rd, Longmeadow, MA 01106-1554 Ph: (413) 567-0885 | Dr Jason L Port, MD 3640 Main St, Suite 101, Springfield, MA 01107-1145 Ph: (413) 781-9000 |
News Archive
Bristol-Myers Squibb Company and Ambrx, Inc. today announced a collaboration under which Bristol-Myers Squibb will receive exclusive worldwide rights to research, develop and commercialize biologics based on Ambrx's research surrounding the Fibroblast Growth Factor 21 protein, for potential use in treating type 2 diabetes, and the Relaxin hormone, for potential use in treating heart failure.
The mitotic spindle, an apparatus that segregates chromosomes during cell division, may be more complex than the standard textbook picture suggests, according to researchers at the Harvard School of Engineering and Applied Sciences.
NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company's third compound to enter the clinic. NOX-H94 is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism.
"The Alzheimer's Association is disappointed to learn of the negative results from the Phase III clinical trial of latrepirdine (Dimebon)," said William Thies, Ph.D., Alzheimer's Association Chief Medical and Scientific Officer. "People with Alzheimer's, their families and caregivers desperately need more and better treatment options for this devastating, fatal brain disease."
› Verified 5 days ago
Laurie E Gianturco, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 1350 Main St Ste 1007, Springfield, MA 01103 Phone: 413-827-7400 Fax: 413-827-7407 | |
Linda Esther Bornstein, MD Radiology Medicare: Medicare Enrolled Practice Location: 3350 Main St, Springfield, MA 01107 Phone: 413-794-9175 Fax: 413-794-5153 | |
Christopher Badalucco, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 759 Chestnut St, Springfield, MA 01107 Phone: 413-827-7400 | |
Christopher C Moore, MD, PH.D Radiology Medicare: Accepting Medicare Assignments Practice Location: 759 Chestnut St, Radiology Department, Springfield, MA 01107 Phone: 413-827-7426 Fax: 413-827-7407 | |
Dr. Thomas Joseph Anderson, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1350 Main St Ste 1007, Springfield, MA 01103 Phone: 413-827-7400 | |
Michael E. Swirsky, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 759 Chestnut St, Radiology Department, Springfield, MA 01107 Phone: 413-827-7426 Fax: 413-827-7407 |